Methods of using adipose derived regenerative cells in the treatment of renal diseases and disorders

• US 9,504,718 B2
• Filed: 03/25/2013
• Issued: 11/29/2016
• Est. Priority Date: 12/07/2001
• Status: Expired due to Term

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H., Daniels, Eric
• Primary Examiner(s): Lankford, Blaine
• Application Number:
  US13/849,900
• Publication Number:
  US 20130344035A1
• Time in Patent Office: 1,345 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2430/26 for kidney reconstruction
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61M 1/3692 Washing or rinsing blood or blood constituents
• CPC Class Codes: A61M 1/3693 using separation based on different densities of components, e.g. centrifuging
• CPC Class Codes: A61M 1/3696 with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
• CPC Class Codes: A61M 2202/0437 Blood stem cells
• CPC Class Codes: A61M 2202/08 Lipoids
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Abstract

Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.

Claims

1. A method for treating a renal disorder associated with ischemia in a subject, comprising:

identifying a subject with impaired renal function; and

administering to the subject an amount of a concentrated population of adipose-derived regenerative cells comprising adipose-derived stem cells and endothelial progenitor cells sufficient to improve function of the kidney of said patient, wherein at least 0.1% of the concentrated population of adipose-derived cells are stem cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells.

2. The method of claim 1, wherein the renal disorder associated with ischemia is identified by assessing serum creatinine levels.

3. The method of claim 1, wherein the renal disorder associated with ischemia is identified by assessing blood urea nitrogen levels.

4. The method of claim 1, wherein the renal disorder associated with ischemia is identified by assessing serum chemistry profiles.

5. The method of claim 1, wherein the renal disorder associated with ischemia is identified by urinalysis.

6. The method of claim 1, wherein the renal disorder associated with ischemia is identified by assessing glomerular filtration rate.

7. The method of claim 1, wherein the subject is provided the concentrated population of adipose-derived regenerative cells within 12 hours after renal failure.

8. The method of claim 1, wherein the subject has post-surgical traumatic injury.

9. The method of claim 1, wherein the concentrated population of adipose-derived regenerative cells is not cultured before being provided to the patient.

10. The method of claim 1, wherein the concentrated population of adipose-derived regenerative cells is autologous.

11. The method of claim 1, wherein the renal disorder associated with ischemia comprises acute tubular necrosis.

12. The method of claim 1, wherein the renal disorder associated with ischemia comprises atherosclerotic renal artery stenosis.

13. The method of claim 1, wherein the administration comprises intravascular or intra-arterial administration.

14. The method of claim 1, wherein the administration comprises administration to the subject'"'"'s renal vasculature.

15. The method of claim 1, wherein the concentrated population of adipose-derived regenerative cells is allogeneic.

16. The method of claim 1, wherein said concentrated population of adipose-derived regenerative cells further comprises an additive.

17. The method of claim 16, wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, and an angiogenic factor.

18. The method of claim 16, wherein the additive reduces the likelihood of adverse reaction on infusion of the concentrated population of adipose-derived regenerative cells into the subject.

19. The method of claim 1, wherein said concentrated population of cells comprising adipose-derived stem cells is cryopreserved.